Antimicrobial resistance (AMR) is one of the greatest global health threats. In 2021 alone, drug-resistant infections caused over one million deaths. Yet the antibiotic pipeline is alarmingly thin. WHO’s 2023 review identified 32 clinical candidates, only 12 of which were considered innovative and just four of which were directed at critical pathogens. The economics of antibiotic development are broken. The investment required is immense, but the returns are minimal. Because the late-stage pipeline is small, commercial risk concentrates on very few assets, which keeps private capital cautious. This pattern reflects economics in which costs are high, and revenues are capped, and the business case for sustained antibiotic R&D collapses.
Antibiotic economics keep R&D returns too low for the pipeline
High development costs, low returns, uncertain long-term effectiveness due to rapid resistance, and antimicrobial stewardship measures together create an economic model that deters sustained antibiotic investment.
High antibiotic R&D costs outrun realistic revenue potential
Pharmaceutical companies face heavy up-front spending on antibiotic development with little chance of recovering it. For patients, the result is fewer treatment options. In the short run, healthcare systems and payers may benefit from lower spending on new antibiotics, but longer-run public health and economic losses from uncontrolled AMR outweigh this.
The short-term cost-revenue imbalance discourages companies from advancing R&D programs, leading to bankruptcies, pipeline stagnation, and loss of expertise. Over time, this widens an innovation gap that leaves few credible assets in late-stage trials. The cost-revenue imbalance signals that market forces alone cannot sustain antibiotic R&D.
Rapid antibiotic resistance cuts the sales window for new drugs
Resistance emerges quickly, cutting short the period when a new antibiotic can earn back its costs. Early on, the sales window shrinks, and risk rises for investors. As resistance spreads, it erodes the effectiveness of entire drug classes. This increases the risk for common medical procedures that depend on antibiotics, and shakes confidence that any single product will remain viable. Faster resistance shortens a drug’s commercial life, which raises revenue uncertainty.
Antimicrobial stewardship caps demand even when new drugs work
Stewardship deliberately restricts prescription volumes, capping the upside even for successful products. At first, utilization falls, and cash flow weakens, which restricts near-term revenues and makes it harder for companies to recover their R&D costs. Over time, those measures preserve clinical effectiveness. But they also convince investors that antibiotics are a capped-growth field. In effect, stewardship secures medical value but signals to investors that even successful drugs might never scale commercially.
“Commercially successful antibiotics have to make at least US$300 million per year, but that is way more than what most new antibiotics are making these days.”– Patrick Heron, General Partner, Frazier Healthcare Partners, 2023
Industry exits expose the antibiotic pipeline to deeper collapse
Big Pharma retreats push antibiotic R&D risk onto SMEs
When large companies withdraw from antibiotics, the pipeline loses not only funding but also the infrastructure and expertise needed to run complex trials. Smaller firms carry programs with limited resources, making projects slower and more fragile. Over time, the absence of big players strips the field of credibility. Without their resources and global reach, investors see antibiotics as a marginal business and discount the chances of commercial success. The retreat of Big Pharma, therefore, shifts development risk to SMEs while also amplifying the sense that the entire field is no longer investable.
SME funding gaps turn antibiotic failures into sector-wide losses
SMEs accounted for three-fourths of late-stage antibiotic programs in 2021, underlining their central role in the global antibiotic pipeline. Yet persistent funding shortages push firms to the edge of collapse, and many antibiotic-focused SMEs face constant bankruptcy risk. One of many examples is Madam Therapeutics in the Netherlands. The company folded in 2023 after the final preclinical stage because it could not secure funding to start its first clinical trials.
Larger pharmaceutical companies and some investors may benefit from reduced competition or acquisition opportunities. But each collapse erodes confidence in the field, tightens funding for future investment, and sends specialist teams elsewhere. This weakens the sector’s capacity to advance future programs.
Related reading:
EU TDEVs for AMR Risk Turning Antibiotic Incentives Into Monopoly Fuel
Talent loss raises the cost of rebuilding antibiotic R&D
The AMR talent pool is relatively small and fragmented, with some 3,000 AMR researchers globally compared with 46,000 in oncology.
Pharma sectors with stronger financial incentives are able to attract these specialists, particularly when antibiotic firms fail, and researchers move into better-funded areas such as oncology or rare diseases. The loss of specialist teams raises restart costs and slows future launches, since rebuilding know-how and project experience is slow and difficult. The brain drain lowers the odds of successful launches and reinforces capital flight.
Taken together, these dynamics form a loop as higher risk drives investors away, fewer backers mean less capacity, and the pipeline remains weak.
Antibiotic markets cannot self-correct without outside support
Health systems need more antibiotic innovation than the market can deliver on its own. Without external correction, innovation capacity will keep falling below the clinical need, no matter how strong the demand becomes.
Push and pull incentives can rebuild the antibiotic market together
Governments and international coalitions are testing solutions to correct the market failure in antibiotics. These efforts fall into two broad approaches: push incentives that lower early-stage R&D costs, and pull incentives that stabilize revenues after approval. Neither works alone, and restoring investor confidence requires a credible mix.
Push funding lowers early antibiotic R&D risk but leaves revenues broken
Push mechanisms reduce up-front R&D risk and help early projects start. Grants and dedicated funds channel support into discovery and early clinical development.
GARDP, set up in 2016 with a goal of three to four treatments by 2028, shows how governments and non-profits now take on projects that private firms no longer pursue. The AMR Action Fund, launched in 2020, is the industry’s attempt to fill part of the gap, but aiming for only two to four launches by 2030 shows how little private-sector commitment remains. By contrast, CARB-X, also founded in 2016, has backed over 100 projects in 13 countries, a proof of breadth, though few advance far enough to become marketable products.
By taking early technical risk off company balance sheets, push funding can bring more candidates forward, lower SMEs’ cost of capital, and draw in investors. Even so, more activity at the start does not fix the revenue problem.
Pull incentives narrow the antibiotic revenue gap after approval
Pull mechanisms help address the revenue gap by rewarding value over volume, which can stabilize returns. Paying for value rather than units sold gives companies a more predictable income stream that can make the field investable again. Pull incentives have been slower to roll out. In many countries, they are still in the pilot phase or under evaluation.
The UK moved first in 2022 with its subscription model, paying developers a fixed annual fee of £5–20 million. The sums might appear modest, but the signal to other governments was clear.
In the USA, the proposed PASTEUR Act (Pioneering Antimicrobial Subscriptions to End Upsurging Resistance) would raise the stakes with contracts between US$750 million and US$3 billion, showing how legislation could shift the market if the legislator does something.
The EU has taken a different route. Its plan for Transferable Data Exclusivity Vouchers (TDEVs) would grant an extra year of regulatory data protection that developers can use or sell as an asset, not just take as a direct payment.
All three pull approaches follow the same principle to pay for value rather than volume. Whether private capital returns will depend on contract size and predictability.
Explore more analysis on EOS Implicium
A mix of push and pull gives antibiotic investors a reason to return
Push incentives lower early-stage barriers, but cannot, on their own, make markets sustainable. Pull mechanisms target revenues but are still limited or untested. Bringing private capital back requires a predictable and stable balance of both.
EOS Implic-Action: Stable contracts keep antibiotics investable
These push and pull strategies recognize the underlying market failure, but their success now depends on clear choices by governments, investors, and industry.
For governments, fragmented schemes create greater budget swings and reliance on costly emergency purchases. For them, moving to steady, multi-year contracts would signal predictability and lower costs over time.
For investors, antibiotics remain a poor bet until pull contracts offer income large and long enough to trust.
For the industry, SMEs will keep driving innovation and carry most of the pipeline, but their survival hinges on post-approval revenues that are stable and visible in advance.
Delay in setting these terms only deepens the sector’s decline, draining assets, talent, and capital from the field.